Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07426484 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Name: Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy — clinical trial record (NCT07426484)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorDana-Farber Cancer Institute

Started2026-04-23

View on ClinicalTrials.gov ↗

Amendment history

2026-08-10

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-07→confirmed 2026-04-23

Study sitesdetails revised at 2 of 2 sites

2026-02-20

Original filing

Dana-Farber Cancer Institute

287 trials monitored

See 33 trials at risk

This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)

Trial Details

NCT Number	NCT07426484
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Checkpoint Therapeutics, Inc.
Conditions	Cutaneous Squamous Cell Carcinoma, Skin Cancer
Enrollment	80 participants
Start Date	2026-04-23
Primary Completion	2030-12-15 (estimated)
Study Completion	2032-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-11